Advances in Targeted Alpha Therapy of Cancer

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2024 Feb 20

PMID 38376807

Authors

Mike Sathekge

Alfred Morgenstern

Affiliations

Soon will be listed here.

References

Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F . An Overview of Targeted Alpha Therapy with Actinium and Bismuth. Curr Radiopharm. 2018; 11(3):200-208. PMC: 6237921. DOI: 10.2174/1874471011666180502104524. View

Sgouros G, Frey E, Du Y, Hobbs R, Bolch W . Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box. Eur J Nucl Med Mol Imaging. 2021; 49(1):18-29. DOI: 10.1007/s00259-021-05583-x. View

Jalloul W, Ghizdovat V, Stolniceanu C, Ionescu T, Grierosu I, Pavaleanu I . Targeted Alpha Therapy: All We Need to Know about Ac's Physical Characteristics and Production as a Potential Theranostic Radionuclide. Pharmaceuticals (Basel). 2023; 16(12). PMC: 10747780. DOI: 10.3390/ph16121679. View

Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel F, Haberkorn U . Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control. J Nucl Med. 2018; 59(5):795-802. DOI: 10.2967/jnumed.117.203539. View

Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T . Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2018; 46(1):129-138. PMC: 6267694. DOI: 10.1007/s00259-018-4167-0. View

Miederer M, Benesova-Schafer M, Mamat C, Kastner D, Pretze M, Michler E . Alpha-Emitting Radionuclides: Current Status and Future Perspectives. Pharmaceuticals (Basel). 2024; 17(1). PMC: 10821197. DOI: 10.3390/ph17010076. View

Eychenne R, Cherel M, Haddad F, Guerard F, Gestin J . Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight". Pharmaceutics. 2021; 13(6). PMC: 8234975. DOI: 10.3390/pharmaceutics13060906. View

Jang A, Kendi A, Johnson G, Halfdanarson T, Sartor O . Targeted Alpha-Particle Therapy: A Review of Current Trials. Int J Mol Sci. 2023; 24(14). PMC: 10380274. DOI: 10.3390/ijms241411626. View

Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C . Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. Eur Urol. 2020; 79(3):343-350. DOI: 10.1016/j.eururo.2020.11.013. View

10.

Sathekge M, Lawal I, Bal C, Bruchertseifer F, Ballal S, Cardaci G . Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024; 25(2):175-183. DOI: 10.1016/S1470-2045(23)00638-1. View

11.

Sathekge M, Bruchertseifer F, Vorster M, Lawal I, Knoesen O, Mahapane J . mCRPC Patients Receiving Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis. J Nucl Med. 2022; 63(10):1496-1502. PMC: 9536711. DOI: 10.2967/jnumed.121.263618. View

12.

Delpassand E, Tworowska I, Esfandiari R, Torgue J, Hurt J, Shafie A . Targeted -Emitter Therapy with Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial. J Nucl Med. 2022; 63(9):1326-1333. PMC: 9454455. DOI: 10.2967/jnumed.121.263230. View

13.

Sgouros G . Dosimetry, Radiobiology and Synthetic Lethality: Radiopharmaceutical Therapy (RPT) With Alpha-Particle-Emitters. Semin Nucl Med. 2020; 50(2):124-132. PMC: 7204891. DOI: 10.1053/j.semnuclmed.2019.11.002. View